{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:04:03Z","timestamp":1793243043558,"version":"4.5.0"},"reference-count":257,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01-CA288278"],"award-info":[{"award-number":["1R01-CA288278"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pharmr.2025.100105","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:32:42Z","timestamp":1763692362000},"page":"100105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting fatty acid synthase for cancer drug discovery: Retrospective analyses and outlook"],"prefix":"10.1016","volume":"78","author":[{"given":"Qingbin","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Josephraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boqing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-9914","authenticated-orcid":false,"given":"Jian-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/carcin\/bgt480","article-title":"Cancer as a metabolic disease: implications for novel therapeutics","volume":"35","author":"Seyfried","year":"2014","journal-title":"Carcinogenesis"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100105_bib2","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1093\/carcin\/bgv037","article-title":"Metabolic reprogramming and dysregulated metabolism: cause, consequence and\/or enabler of environmental carcinogenesis?","volume":"36","author":"Robey","year":"2015","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib3","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1038\/s41467-018-07232-8","article-title":"Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas","volume":"9","author":"Rosario","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gendis.2017.02.003","article-title":"Aerobic glycolysis and high level of lactate in cancer metabolism and microenvironment","volume":"4","author":"Jiang","year":"2017","journal-title":"Genes Dis"},{"key":"10.1016\/j.pharmr.2025.100105_bib7","article-title":"Metabolism of amino acids in cancer","volume":"8","author":"Wei","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer"},{"issue":"1 Pt 2","key":"10.1016\/j.pharmr.2025.100105_bib11","first-page":"R146","article-title":"Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor","volume":"247","author":"Ookhtens","year":"1984","journal-title":"Am J Physiol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmr.2025.100105_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605154","article-title":"The lipid metabolic landscape of cancers and new therapeutic perspectives","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib14","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/cancers13051132","article-title":"Fatty acid synthase confers tamoxifen resistance to ER+\/HER2+ Breast Cancer","volume":"13","author":"Menendez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1373\/clinchem.2008.115352","article-title":"Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer","volume":"55","author":"Menendez","year":"2009","journal-title":"Clin Chem"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100105_bib16","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-15-0126","article-title":"Molecular pathways: fatty acid synthase","volume":"21","author":"Jones","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib17","first-page":"69","article-title":"Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis\/prognosis marker","volume":"1","author":"Liu","year":"2010","journal-title":"Int J Biochem Mol Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJM198909073211003","article-title":"Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease","volume":"321","author":"Kuhajda","year":"1989","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100105_bib19","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1073\/pnas.91.14.6379","article-title":"Fatty acid synthesis: a potential selective target for antineoplastic therapy","volume":"91","author":"Kuhajda","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K","article-title":"Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients","volume":"77","author":"Alo\u2019","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/030089169908500108","article-title":"Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas","volume":"85","author":"Al\u00f2","year":"1999","journal-title":"Tumori"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"R\u00f6hrig","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib23","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.bbalip.2013.07.008","article-title":"Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids","volume":"1831","author":"Louie","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100105_bib24","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00018-019-03092-7","article-title":"Palmitic acid is an intracellular signaling molecule involved in disease development","volume":"76","author":"Fatima","year":"2019","journal-title":"Cell Mol Life Sci"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100105_bib25","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.7150\/ijbs.45640","article-title":"S-Palmitoylation as a functional regulator of proteins associated with cisplatin resistance in bladder cancer","volume":"16","author":"Shahid","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100105_bib26","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.7150\/ijbs.64046","article-title":"Lipid-induced S-palmitoylation as a vital regulator of cell signaling and disease development","volume":"17","author":"Qu","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3945\/ajcn.113.070557","article-title":"Dietary intake of palmitate and oleate has broad impact on systemic and tissue lipid profiles in humans","volume":"99","author":"Kien","year":"2014","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1203\/00006450-197208000-00005","article-title":"In vitro metabolism of palmitic acid in human fetal tissue","volume":"6","author":"Yoshioka","year":"1972","journal-title":"Pediatr Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib29","doi-asserted-by":"crossref","first-page":"R431","DOI":"10.1016\/j.cub.2013.04.024","article-title":"Covalent lipid modifications of proteins","volume":"23","author":"Resh","year":"2013","journal-title":"Curr Biol"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100105_bib30","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.4161\/cc.29338","article-title":"Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells","volume":"13","author":"Bollu","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmr.2025.100105_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-394622-5.00010-9","article-title":"Palmitoylation of Hedgehog proteins","volume":"88","author":"Buglino","year":"2012","journal-title":"Vitam Horm"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/onc.2010.454","article-title":"Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma","volume":"30","author":"Bhatia","year":"2011","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib33","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib34","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/cam4.711","article-title":"Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway","volume":"5","author":"Wang","year":"2016","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib35","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200414","article-title":"Palmitoylation of Hedgehog proteins by Hedgehog acyltransferase: roles in signalling and disease","volume":"11","author":"Resh","year":"2021","journal-title":"Open Biol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100105_bib36","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.3390\/ijms26125721","article-title":"Downregulation of S6 kinase and hedgehog-Gli1 by inhibition of fatty acid synthase in AML with FLT3-ITD mutation","volume":"26","author":"Kebenko","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1042\/BST20160233","article-title":"Palmitoylation of proteins in cancer","volume":"45","author":"Resh","year":"2017","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib38","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ebiom.2015.06.020","article-title":"Inhibition of de novo palmitate Synthesis by fatty acid synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression","volume":"2","author":"Ventura","year":"2015","journal-title":"EBiomedicine"},{"key":"10.1016\/j.pharmr.2025.100105_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ebiom.2016.12.012","volume":"16","author":"Heuer","year":"2017","journal-title":"EBiomedicine"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib40","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-23-0966","article-title":"FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib41","first-page":"594","article-title":"Small interfering RNA-mediated knockdown of fatty acid synthase attenuates the proliferation and metastasis of human gastric cancer cells via the mTOR\/Gli1 signaling pathway","volume":"16","author":"Sun","year":"2018","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib42","doi-asserted-by":"crossref","first-page":"11600","DOI":"10.18632\/oncotarget.14591","article-title":"Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells","volume":"8","author":"Wagner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmr.2025.100105_bib43","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.2147\/OTT.S199369","article-title":"Fatty acid synthase enhances colorectal cancer cell proliferation and metastasis via regulating AMPK\/mTOR pathway","volume":"12","author":"Lu","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.cmet.2018.07.019","article-title":"Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation","volume":"28","author":"Bruning","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41389-023-00460-8","article-title":"Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies","volume":"12","author":"Vanauberg","year":"2023","journal-title":"Oncogenesis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib46","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3892\/mmr.2012.1220","article-title":"Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration via downregulation of the PI3K\/Akt signaling pathway in vitro","volume":"7","author":"Liu","year":"2013","journal-title":"Mol Med Rep"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100105_bib47","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2174\/13816128113199990486","article-title":"Targeting SREBP-1-driven lipid metabolism to treat cancer","volume":"20","author":"Guo","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100105_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34029","article-title":"Integrative analysis of anoikis-related genes reveals that FASN is a novel prognostic biomarker and promotes the malignancy of bladder cancer via Wnt\/beta-catenin pathway","volume":"10","author":"Peng","year":"2024","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033738","article-title":"Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma","volume":"7","author":"Gelebart","year":"2012","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-07-0445","article-title":"A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction","volume":"7","author":"Liu","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib51","first-page":"89","article-title":"Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers","volume":"2","author":"Yang","year":"2011","journal-title":"Int J Biochem Mol Biol"},{"issue":"45","key":"10.1016\/j.pharmr.2025.100105_bib52","doi-asserted-by":"crossref","first-page":"E6965","DOI":"10.1073\/pnas.1609934113","article-title":"FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-\u03baB and SP1","volume":"113","author":"Wu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib53","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10495-017-1366-2","article-title":"Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis","volume":"22","author":"Al-Bahlani","year":"2017","journal-title":"Apoptosis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib54","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/cancers15030562","article-title":"Enhanced de novo lipid synthesis mediated by FASN induces chemoresistance in colorectal cancer","volume":"15","author":"Han","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100529","article-title":"FASN negatively regulates p65 expression by reducing its stability via Thr","volume":"65","author":"Barlow","year":"2024","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib56","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1194\/jlr.M033811","article-title":"Fatty acid synthase causes drug resistance by inhibiting TNF-alpha and ceramide production","volume":"54","author":"Liu","year":"2013","journal-title":"J Lipid Res"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100105_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216503","article-title":"Resensitizing paclitaxel-resistant ovarian cancer via targeting lipid metabolism key enzymes CPT1A, SCD and FASN","volume":"24","author":"Ma","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10549-021-06231-6","article-title":"FASN inhibition as a potential treatment for endocrine-resistant breast cancer","volume":"187","author":"Gruslova","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-024-04867-8","article-title":"Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"J Transl Med"},{"issue":"37","key":"10.1016\/j.pharmr.2025.100105_bib60","doi-asserted-by":"crossref","first-page":"24787","DOI":"10.18632\/oncotarget.25361","article-title":"Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer","volume":"9","author":"Zaytseva","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1158\/1541-7786.MCR-18-0199","article-title":"De novo fatty acid synthesis-driven sphingolipid metabolism promotes metastatic potential of colorectal cancer","volume":"17","author":"Jafari","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13046-023-02664-7","article-title":"Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy","volume":"42","author":"Talebi","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.pharmr.2025.100105_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalmedicine"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2020","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100105_bib65","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","article-title":"Phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13048-021-00886-x","article-title":"Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics","volume":"14","author":"Franz","year":"2021","journal-title":"J Ovarian Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100105_bib67","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.bmcl.2018.05.014","article-title":"Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy","volume":"28","author":"Lu","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib68","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nchembio.1603","article-title":"A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site","volume":"10","author":"Hardwicke","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.pharmr.2025.100105_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105321","article-title":"Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells","volume":"149","author":"Singha","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib70","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3390\/molecules27051552","article-title":"Synthesis and evaluation of (11)C-labeled triazolones as probes for imaging fatty acid synthase expression by positron emission tomography","volume":"27","author":"Kelly","year":"2022","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib71","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.chembiol.2019.06.004","article-title":"Mechanistic MALDI-TOF cell-based assay for the discovery of potent and specific fatty acid synthase inhibitors","volume":"26","author":"Weigt","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100105_bib72","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1016\/j.bmcl.2011.07.083","article-title":"Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure","volume":"21","author":"Kley","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib73","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bmcl.2019.02.012","article-title":"Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN)","volume":"29","author":"Martin","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib74","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.chembiol.2016.04.011","article-title":"Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer","volume":"23","author":"Alwarawrah","year":"2016","journal-title":"Cell Chem Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101550","article-title":"Fasnall induces atypically transient stress granules independently of FASN inhibition","volume":"23","author":"Amen","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.pharmr.2025.100105_bib76","series-title":"Sulfonamide Derivatives for Therapeutic Use as Fatty Acid Synthase Inhibitors","author":"Butlin","year":"2007"},{"key":"10.1016\/j.pharmr.2025.100105_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2020.104707","article-title":"Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines","volume":"113","author":"Aquino","year":"2020","journal-title":"Arch Oral Biol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100105_bib78","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/acsptsci.3c00182","article-title":"Fatty acid synthase inhibitors enhance microtubule-stabilizing and microtubule-destabilizing drugs in taxane-resistant prostate cancer cells","volume":"6","author":"Souchek","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.pharmr.2025.100105_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101143","article-title":"Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer","volume":"62","author":"Steen","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmr.2025.100105_bib80","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3389\/fonc.2020.01185","article-title":"Inhibition of fatty acid synthase upregulates expression of CD36 to sustain proliferation of colorectal cancer cells","volume":"10","author":"Drury","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.pharmr.2025.100105_bib81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2020.12.032","article-title":"Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors","volume":"153","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100105_bib82","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1021\/acs.jcim.0c00898","article-title":"Substitution effect of the trifluoromethyl group on the bioactivity in medicinal chemistry: Statistical analysis and energy calculations","volume":"60","author":"Abula","year":"2020","journal-title":"J Chem Inf Model"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib83","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100105_bib84","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib85","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41523-024-00656-0","article-title":"Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion","volume":"10","author":"Serhan","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib86","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1021\/acs.jproteome.4c00252","article-title":"FAS inhibited proteomics and phosphoproteomics profiling of colorectal cancer spheroids shows activation of ferroptotic death mechanism","volume":"23","author":"Fries","year":"2024","journal-title":"J Proteome Res"},{"key":"10.1016\/j.pharmr.2025.100105_bib87","doi-asserted-by":"crossref","unstructured":"Josephraj S, Wang CJ, Cui Q, Dong Z, Liu J-Y, Zhang J-T. Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer. Genes Dis. 2026;13(1):101817. https:\/\/doi.org\/10.1016\/j.gendis.2025.101817.","DOI":"10.1016\/j.gendis.2025.101817"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib88","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1038\/s41467-023-39266-y","article-title":"Atomic model for core modifying region of human fatty acid synthase in complex with Denifanstat","volume":"14","author":"Hasan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2025.100105_bib89","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2014-4747","article-title":"Design and synthesis of a series highly potent and bioavailable FASN KR domain inhibitors for cancer","volume":"74","author":"Lu","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib90","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1038\/s41467-021-27329-x","article-title":"Metabolic drug survey highlights cancer cell dependencies and vulnerabilities","volume":"12","author":"Pemovska","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib91","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.3390\/cells9112447","article-title":"Deciphering fatty acid synthase inhibition-triggered metabolic flexibility in prostate cancer cells through untargeted metabolomics","volume":"9","author":"Oh","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib92","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41589-019-0344-0","article-title":"Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation","volume":"15","author":"Kim","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.pharmr.2025.100105_bib93","article-title":"Identification of Fasnall as a therapeutically effective Complex I inhibitor","author":"Mukha","year":"2024","journal-title":"bioRxiv"},{"issue":"1\u20133","key":"10.1016\/j.pharmr.2025.100105_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib95","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1349-7006.2010.01596.x","article-title":"Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice","volume":"101","author":"Murata","year":"2010","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12177-011-9065-7","article-title":"Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells","volume":"3","author":"Deepa","year":"2010","journal-title":"J Ocul Biol Dis Infor"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib97","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41419-022-04926-2","article-title":"FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis","volume":"13","author":"Du","year":"2022","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib98","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3892\/ijo.2013.1978","article-title":"Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells","volume":"43","author":"Shiragami","year":"2013","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib99","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10495-012-0776-4","article-title":"Fatty acid synthase inhibitor cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis","volume":"18","author":"Jeong","year":"2013","journal-title":"Apoptosis"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib100","first-page":"771","article-title":"FASN inhibitors enhance bestatin-related tumor cell apoptosis through upregulating PepT1","volume":"16","author":"Ni","year":"2023","journal-title":"Curr Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib101","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.adro.2020.06.022","article-title":"Cytotoxicity and radiosensitizing activity of the fatty acid synthase inhibitor C75 is enhanced by blocking fatty acid uptake in prostate cancer cells","volume":"5","author":"Rae","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100105_bib102","doi-asserted-by":"crossref","first-page":"17184","DOI":"10.1074\/jbc.M114.550806","article-title":"4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid (C75), an inhibitor of fatty-acid synthase, suppresses the mitochondrial fatty acid synthesis pathway and impairs mitochondrial function","volume":"289","author":"Chen","year":"2014","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib103","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/chir.22139","article-title":"Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity","volume":"25","author":"Makowski","year":"2013","journal-title":"Chirality"},{"key":"10.1016\/j.pharmr.2025.100105_bib104","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejmech.2017.03.012","article-title":"(-)-UB006: A new fatty acid synthase inhibitor and cytotoxic agent without anorexic side effects","volume":"131","author":"Makowski","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cbt.10.6.12727","article-title":"High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy","volume":"10","author":"Orita","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.pharmr.2025.100105_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/285191","article-title":"Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas","volume":"2010","author":"Ueda","year":"2010","journal-title":"J Oncol"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100105_bib107","doi-asserted-by":"crossref","first-page":"31457","DOI":"10.1074\/jbc.M111.274308","article-title":"Nuclear factor-kappaB (NF-kappaB) mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase","volume":"286","author":"Lemmon","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41392-022-01099-4","article-title":"Discovery of a mammalian FASN inhibitor against xenografts of non-small cell lung cancer and melanoma","volume":"7","author":"Cao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib109","first-page":"344","article-title":"Studies on cerulenin, 3. Isolation and physico-chemical properties of cerulenin","volume":"20","author":"Sato","year":"1967","journal-title":"J Antibiot (Tokyo)"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib110","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/oxfordjournals.jbchem.a129827","article-title":"The action mechanism of cerulenin. I. Effect of cerulenin on sterol and fatty acid biosynthesis in yeast","volume":"71","author":"Nomura","year":"1972","journal-title":"J Biochem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib111","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/oxfordjournals.jbchem.a122739","article-title":"Binding site of cerulenin in fatty acid synthetase","volume":"105","author":"Funabashi","year":"1989","journal-title":"J Biochem"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100105_bib112","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/cancers14184491","article-title":"Concomitant inhibition of FASN and SREBP provides a promising therapy for CTCL","volume":"14","author":"Chi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075980","article-title":"Cerulenin blockade of fatty acid synthase reverses hepatic steatosis in ob\/ob mice","volume":"8","author":"Cheng","year":"2013","journal-title":"PLOS One"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib114","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1210\/en.2004-0039","article-title":"Carnitine palmitoyltransferase-1 (CPT-1) activity stimulation by cerulenin via sympathetic nervous system activation overrides cerulenin\u2019s peripheral effect","volume":"145","author":"Jin","year":"2004","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib115","doi-asserted-by":"crossref","first-page":"R352","DOI":"10.1152\/ajpregu.00862.2006","article-title":"Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight","volume":"294","author":"Aja","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib116","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.97.7.3450","article-title":"Synthesis and antitumor activity of an inhibitor of fatty acid synthase","volume":"97","author":"Kuhajda","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib117","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/cas.16085","article-title":"Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms","volume":"115","author":"Zhang","year":"2024","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib118","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1021\/jm049389h","article-title":"Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase","volume":"48","author":"McFadden","year":"2005","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib119","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1158\/0008-5472.CAN-06-3439","article-title":"Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells","volume":"67","author":"Zhou","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmr.2025.100105_bib120","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fonc.2019.01412","article-title":"Pathogenetic, prognostic, and therapeutic role of fatty acid synthase in human hepatocellular carcinoma","volume":"9","author":"Che","year":"2019","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100105_bib121","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1073\/pnas.1002588108","article-title":"Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes","volume":"108","author":"Wu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib122","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbagen.2013.09.020","article-title":"Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype","volume":"1840","author":"Kant","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib123","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.bbagen.2012.07.010","article-title":"Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules","volume":"1820","author":"Kant","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49486-2","article-title":"Fatty acid inhibition sensitizes androgen-dependent and -independent prostate cancer to radiotherapy via FASN\/NF-\u03baB pathway","volume":"9","author":"Chuang","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopha.2011.02.016","article-title":"Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal","volume":"65","author":"Chuang","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100105_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.03.026","article-title":"Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase","volume":"509","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib127","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1021\/jm501543u","article-title":"Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase","volume":"58","author":"Fako","year":"2015","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100105_bib128","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.1158\/1078-0432.CCR-21-0493","article-title":"Inhibiting fatty acid synthase with omeprazole to improve efficacy of neoadjuvant chemotherapy in patients with operable TNBC","volume":"27","author":"Sardesai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib129","article-title":"Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119","volume":"73","author":"Brophy","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1073\/pnas.1808834116","article-title":"Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer","volume":"116","author":"Zadra","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib131","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.119.258947","article-title":"An inhibitor of fatty acid synthase thioesterase domain with improved cytotoxicity against breast cancer cells and stability in plasma","volume":"371","author":"Lupien","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib132","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","article-title":"Orlistat, a new lipase inhibitor for the management of obesity","volume":"20","author":"Heck","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib133","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Biomed Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib134","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-03-3645","article-title":"Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity","volume":"64","author":"Kridel","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib135","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/annonc\/mdi239","article-title":"Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2\/neu (erbB-2) oncogene","volume":"16","author":"Menendez","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib136","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11745-009-3298-2","article-title":"Inhibition of fatty acid synthase by orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo","volume":"44","author":"Dowling","year":"2009","journal-title":"Lipids"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib137","first-page":"6321","article-title":"Orlistat reduces proliferation and enhances apoptosis in human pancreatic cancer cells (PANC-1)","volume":"37","author":"Sokolowska","year":"2017","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib138","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1158\/1535-7163.MCT-12-1136","article-title":"The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas","volume":"13","author":"Agostini","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib139","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.23835","article-title":"Fatty acid synthase inhibition with orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model","volume":"123","author":"Carvalho","year":"2008","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00210-018-1579-0","article-title":"Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions","volume":"392","author":"Saleh","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib141","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1158\/1535-7163.MCT-14-0183","article-title":"Lipid catabolism via CPT1 as a therapeutic target for prostate cancer","volume":"13","author":"Schlaepfer","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib142","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3390\/cancers13092284","article-title":"Deregulated FASN expression in BRAF inhibitor-resistant melanoma cells unveils new targets for drug combinations","volume":"13","author":"Stamatakos","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib143","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13023-020-01499-1","article-title":"Synergistic apoptosis following endoplasmic reticulum stress aggravation in mucinous colon cancer","volume":"15","author":"Dilly","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib144","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2450859","article-title":"NVP-2, in combination with orlistat, represents a promising therapeutic strategy for acute myeloid leukemia","volume":"26","author":"Zhu","year":"2025","journal-title":"Cancer Biol Ther"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100105_bib145","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1021\/acs.jmedchem.2c00642","article-title":"Therapeutic activity of the lansoprazole metabolite 5-hydroxy lansoprazole sulfide in triple-negative breast cancer by inhibiting the enoyl reductase of fatty acid synthase","volume":"65","author":"Beebe","year":"2022","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib146","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/acs.chemrestox.8b00269","article-title":"Orlistat displays antitumor activity and enhances the efficacy of paclitaxel in human hepatoma Hep3B cells","volume":"32","author":"You","year":"2019","journal-title":"Chem Res Toxicol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib147","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/1535-7163.MCT-17-0013","article-title":"Combination treatment with orlistat-containing nanoparticles and taxanes is synergistic and enhances microtubule stability in taxane-resistant prostate cancer cells","volume":"16","author":"Souchek","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib148","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3390\/cells10082060","article-title":"Anti-obesity drug orlistat alleviates western-diet-driven colitis-associated colon cancer via inhibition of STAT3 and NF-\u03baB-mediated signaling","volume":"10","author":"Jin","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib149","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3892\/ijo.2012.1465","article-title":"Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with orlistat","volume":"41","author":"Huang","year":"2012","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/1120009X.2019.1694761","article-title":"Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line","volume":"32","author":"Cioccoloni","year":"2020","journal-title":"J Chemother"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib151","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/ja907716f","article-title":"Activity-based proteome profiling of potential cellular targets of orlistat\u2014an FDA-approved drug with anti-tumor activities","volume":"132","author":"Yang","year":"2010","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib152","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/13543784.2018.1471132","article-title":"Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy","volume":"27","author":"Schcolnik-Cabrera","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmr.2025.100105_bib153","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5039","article-title":"Risk of colorectal cancer after initiation of orlistat: matched cohort study","volume":"347","author":"Hong","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib154","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/01635581.2022.2108467","article-title":"Proton pump inhibitor use and obesity-associated cancer in the Women\u2019s Health Initiative","volume":"75","author":"Ballinger","year":"2023","journal-title":"Nutr Cancer"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib156","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jgh.15236","article-title":"Proton pump inhibitors use and the risk of fatty liver disease: a nationwide cohort study","volume":"36","author":"Pyo","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"suppl 2","key":"10.1016\/j.pharmr.2025.100105_bib157","first-page":"S10","article-title":"Proton pump inhibitor use and enteric infections","volume":"104","author":"Dial","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib158","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","article-title":"Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis","volume":"11","author":"Lo","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib159","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2016.09.007","article-title":"Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in A population study","volume":"152","author":"Tsai","year":"2017","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib160","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1158\/1078-0432.CCR-08-1946","article-title":"Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors","volume":"15","author":"Satoh","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100105_bib161","doi-asserted-by":"crossref","first-page":"16515","DOI":"10.1021\/acs.jmedchem.3c01130","article-title":"Small molecule inhibitors targeting the \u201cUndruggable\u201d survivin: the past, present, and future from a medicinal chemist\u2019s perspective","volume":"66","author":"Cui","year":"2023","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100105_bib162","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.18632\/oncotarget.2433","article-title":"The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer","volume":"5","author":"Sadowski","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmr.2025.100105_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174261","article-title":"Triclosan down-regulates fatty acid synthase through microRNAs in HepG2 cells","volume":"907","author":"Sun","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib164","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/1573406415666190306152907","article-title":"Synthesis, biological evaluation and molecular dynamics simulation studies of novel diphenyl ethers","volume":"16","author":"Khade","year":"2020","journal-title":"Med Chem"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100105_bib165","doi-asserted-by":"crossref","first-page":"30316","DOI":"10.1074\/jbc.273.46.30316","article-title":"Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis","volume":"273","author":"Heath","year":"1998","journal-title":"J Biol Chem"},{"issue":"48","key":"10.1016\/j.pharmr.2025.100105_bib166","doi-asserted-by":"crossref","first-page":"33287","DOI":"10.1074\/jbc.M114.608547","article-title":"Crystal structure of the human fatty acid synthase enoyl-acyl carrier protein-reductase domain complexed with triclosan reveals allosteric protein-protein interface inhibition","volume":"289","author":"Sippel","year":"2014","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib167","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00280-001-0399-x","article-title":"Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells","volume":"49","author":"Liu","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100105_bib168","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/ncomms8659","article-title":"Lansoprazole is an antituberculous prodrug targeting cytochrome bc1","volume":"6","author":"Rybniker","year":"2015","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib169","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat Prod"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib170","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3892\/mmr.2017.6254","article-title":"Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis","volume":"15","author":"Lee","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharmr.2025.100105_bib171","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3389\/fphar.2019.00709","article-title":"Emodin induced SREBP1-dependent and SREBP1-independent apoptosis in hepatocellular carcinoma cells","volume":"10","author":"Yang","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib172","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/acs.jafc.2c05334","article-title":"Phase I metabolism of Pterostilbene, a dietary resveratrol derivative: metabolite identification, species differences, isozyme contribution, and further bioactivation","volume":"71","author":"Li","year":"2023","journal-title":"J Agric Food Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib173","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00535-012-0612-1","article-title":"The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells","volume":"48","author":"Kwan","year":"2013","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib174","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2014.12.086","article-title":"Oridonin induces apoptosis in uveal melanoma cells by upregulation of Bim and downregulation of fatty acid synthase","volume":"457","author":"Gu","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/jcp.24258","article-title":"Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2-overexpressing cancer cells","volume":"228","author":"Do","year":"2013","journal-title":"J Cell Physiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib176","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1021\/jf100352c","article-title":"Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt\/mTOR pathway","volume":"58","author":"Lin","year":"2010","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.pharmr.2025.100105_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172788","article-title":"Osthole delays hepatocarcinogenesis in mice by suppressing AKT\/FASN axis and ERK phosphorylation","volume":"867","author":"Mo","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100105_bib178","article-title":"Emodin protects SH-SY5Y cells against zinc-induced synaptic impairment and oxidative stress through the ERK1\/2 pathway","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib179","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3390\/ani11113314","article-title":"Emodin improves intestinal health and immunity through modulation of gut microbiota in mice infected by pathogenic Escherichia coli O1","volume":"11","author":"Gao","year":"2021","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.pharmr.2025.100105_bib180","article-title":"Emodin-mediated treatment of acute kidney injury","volume":"2022","author":"Liu","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17052","article-title":"Emodin attenuates high lipid-induced liver metastasis through the AKT and ERK pathways in vitro in breast cancer cells and in a mouse xenograft model","volume":"9","author":"Li","year":"2023","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib182","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3748\/wjg.v11.i9.1339","article-title":"Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw","volume":"11","author":"Dong","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharmr.2025.100105_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114340","article-title":"Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway","volume":"279","author":"Shen","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.pharmr.2025.100105_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115123","article-title":"Pharmacokinetics and metabolism of trans-emodin dianthrones in rats","volume":"290","author":"Song","year":"2022","journal-title":"J Ethnopharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib185","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1248\/cpb.51.790","article-title":"Ent-kaurane diterpenoids from Isodon rubescens var lushanensis","volume":"51","author":"Han","year":"2003","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.pharmr.2025.100105_bib186","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3167959","article-title":"Oridonin relieves angiotensin II-induced cardiac remodeling via inhibiting GSDMD-mediated inflammation","volume":"2022","author":"Lin","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.pharmr.2025.100105_bib187","article-title":"Oridonin: a review of its pharmacology, pharmacokinetics and toxicity","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib188","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jpha.2023.08.010","article-title":"Oridonin restores hepatic lipid homeostasis in an LXRalpha-ATGL\/EPT1 axis-dependent manner","volume":"13","author":"Chen","year":"2023","journal-title":"J Pharm Anal"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib189","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s11596-020-2262-5","article-title":"Anti-inflammatory activity of mollugin on DSS-induced colitis in mice","volume":"40","author":"Li","year":"2020","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.pharmr.2025.100105_bib190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.micpath.2019.05.007","article-title":"Regulation of NF-\u03baB\/MAPK signaling pathway attenuates the acute lung inflammation in Klebsiella pneumonia rats by mollugin treatment","volume":"132","author":"Zhang","year":"2019","journal-title":"Microb Pathog"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib191","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.phymed.2013.01.014","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance is induced by mollugin in MCF-7\/adriamycin cells","volume":"20","author":"Tran","year":"2013","journal-title":"Phytomedicine"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib192","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.3390\/molecules26113249","article-title":"Synthesis and antitumor activity of 1-substituted 1,2,3-triazole-mollugin derivatives","volume":"26","author":"Luo","year":"2021","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100105_bib193","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.2174\/1389557520666200709175948","article-title":"Osthole: A multifunctional natural compound with potential anticancer, antioxidant and anti-inflammatory activities","volume":"21","author":"Zafar","year":"2021","journal-title":"Mini Rev Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib194","first-page":"297","article-title":"Osthole: a promising lead compound for drug discovery from a traditional Chinese medicine (TCM)","volume":"4","author":"You","year":"2009","journal-title":"Nat Prod Commun"},{"key":"10.1016\/j.pharmr.2025.100105_bib195","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/919616","article-title":"Osthole: a review on its bioactivities, pharmacological properties, and potential as alternative medicine","volume":"2015","author":"Zhang","year":"2015","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.pharmr.2025.100105_bib196","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exger.2019.01.014","article-title":"Osthole inhibits oleic acid\/lipopolysaccharide-induced lipid accumulation and inflammatory response through activating PPARalpha signaling pathway in cultured hepatocytes","volume":"119","author":"Zhao","year":"2019","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.pharmr.2025.100105_bib197","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1471-2407-12-280","article-title":"Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer","volume":"12","author":"Relat","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmr.2025.100105_bib198","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12935-018-0539-6","article-title":"Epistructured catechins, EGCG and EC facilitate apoptosis induction through targeting de novo lipogenesis pathway in HepG2 cells","volume":"18","author":"Khiewkamrop","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100105_bib199","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1158\/1078-0432.CCR-15-3133","article-title":"Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer","volume":"22","author":"Gir\u00f3-Perafita","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib200","doi-asserted-by":"crossref","first-page":"740","DOI":"10.20892\/j.issn.2095-3941.2020.0219","article-title":"Targeting fatty acid synthase sensitizes human nasopharyngeal carcinoma cells to radiation via downregulating frizzled class receptor 10","volume":"17","author":"Chen","year":"2020","journal-title":"Cancer Biol Med"},{"issue":"1058","key":"10.1016\/j.pharmr.2025.100105_bib201","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150665","article-title":"Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy","volume":"89","author":"Zhao","year":"2016","journal-title":"Br J Radiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib202","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3077","article-title":"A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines","volume":"13","author":"Puig","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib203","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051283","article-title":"Fatty acid synthase inhibitor G28 shows anticancer activity in EGFR tyrosine kinase inhibitor resistant lung adenocarcinoma models","volume":"12","author":"Polonio-Alcala","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2025.100105_bib204","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11010-010-0707-z","article-title":"Suppression of fatty acid synthase, differentiation and lipid accumulation in adipocytes by curcumin","volume":"351","author":"Zhao","year":"2011","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11523-013-0286-5","article-title":"Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase","volume":"9","author":"Fan","year":"2014","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib206","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3892\/or.2016.4682","article-title":"Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells","volume":"35","author":"Fan","year":"2016","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib207","doi-asserted-by":"crossref","DOI":"10.5812\/ijcm.8173","article-title":"Effect of curcumin on fatty acid synthase expression and enzyme activity in breast cancer cell line SKBR3","volume":"10","author":"Younesian","year":"2017","journal-title":"Int J Cancer Manag"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib208","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.21037\/jgo-22-259","article-title":"A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer","volume":"13","author":"Gunther","year":"2022","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib209","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-018-3654-0","article-title":"A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc\u2122) in patients with locally advanced or metastatic cancer","volume":"82","author":"Greil","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib210","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-010-1300-6","article-title":"Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase","volume":"130","author":"Pandey","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib211","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.canep.2014.09.006","article-title":"Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway","volume":"38","author":"Khan","year":"2014","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib212","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjh.12154","article-title":"A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma","volume":"160","author":"Popat","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib213","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/1940-6207.CAPR-11-0148","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases\u2014safety, pharmacokinetics, and pharmacodynamics","volume":"4","author":"Howells","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib214","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3892\/ol.2014.2159","article-title":"Quercetin induces HepG2 cell apoptosis by inhibiting fatty acid biosynthesis","volume":"8","author":"Zhao","year":"2014","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib215","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1475-2867-12-34","article-title":"Quercetin-induced inhibition and synergistic activity with cisplatin\u2014a chemotherapeutic strategy for nasopharyngeal carcinoma cells","volume":"12","author":"Daker","year":"2012","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib216","first-page":"659","article-title":"Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition","volume":"2","author":"Ferry","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib217","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11306-011-0300-9","article-title":"Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75","volume":"8","author":"Harris","year":"2012","journal-title":"Metabolomics"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib218","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.7b00154","article-title":"How frequently are pan-assay interference compounds active? Large-scale analysis of screening data reveals diverse activity profiles, low global hit frequency, and many consistently inactive compounds","volume":"60","author":"Jasial","year":"2017","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib219","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/antiox10071076","article-title":"Green tea and epigallocatechin gallate (EGCG) for the management of nonalcoholic fatty liver diseases (NAFLD): insights into the role of oxidative stress and antioxidant mechanism","volume":"10","author":"Tang","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100105_bib220","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13789","article-title":"Curcumin supplementation mitigates NASH development and progression in female Wistar rats","volume":"6","author":"Cunningham","year":"2018","journal-title":"Physiol Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib221","first-page":"559","article-title":"Effect of resveratrol on non-alcoholic fatty liver disease","volume":"18","author":"Theodotou","year":"2019","journal-title":"Exp Ther Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100105_bib222","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/antiox13111286","article-title":"Exploratory role of flavonoids on metabolic dysfunction-associated steatotic liver disease (MASLD) in a South Italian cohort","volume":"13","author":"Bonfiglio","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib223","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1006\/bbrc.2001.5923","article-title":"Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase","volume":"288","author":"Wang","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100105_bib224","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-007-9678-5","article-title":"Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75","volume":"109","author":"Puig","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib225","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2174\/092986706776361012","article-title":"Inhibition of fatty acid synthase by polyphenols","volume":"13","author":"Tian","year":"2006","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib226","doi-asserted-by":"crossref","DOI":"10.1093\/cdn\/nzz101","article-title":"Molecular mechanisms of epigallocatechin-3-gallate for prevention of chronic kidney disease and renal fibrosis: preclinical evidence","volume":"3","author":"Kanlaya","year":"2019","journal-title":"Curr Dev Nutr"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib227","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3390\/molecules23092346","article-title":"Bioavailability of tea catechins and its improvement","volume":"23","author":"Cai","year":"2018","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib228","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The essential medicinal chemistry of curcumin","volume":"60","author":"Nelson","year":"2017","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100105_bib229","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/acsmedchemlett.7b00284","article-title":"A realistic view on \u201cthe essential medicinal chemistry of curcumin\u201d","volume":"8","author":"Bahadori","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100105_bib230","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/biom11071025","article-title":"The demethoxy derivatives of curcumin exhibit greater differentiation suppression in 3T3-L1 adipocytes than curcumin: A mechanistic study of adipogenesis and molecular docking","volume":"11","author":"Alalaiwe","year":"2021","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib231","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.drudis.2017.05.017","article-title":"Pan-assay interference compounds (PAINS) that may not be too painful for chemical biology projects","volume":"22","author":"Lagorce","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.pharmr.2025.100105_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112356","article-title":"Resveratrol\u2014a comprehensive review of recent advances in anticancer drug design and development","volume":"200","author":"Ahmadi","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100105_bib233","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41698-017-0038-6","article-title":"The therapeutic potential of resveratrol: a review of clinical trials","volume":"1","author":"Berman","year":"2017","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib234","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4155\/ppa-2017-0030","article-title":"Therapeutic charm of quercetin and its derivatives: a review of research and patents","volume":"7","author":"Sharma","year":"2018","journal-title":"Pharm Pat Anal"},{"key":"10.1016\/j.pharmr.2025.100105_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117463","article-title":"A review on anti-cancer properties of quercetin in breast cancer","volume":"248","author":"Ezzati","year":"2020","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib236","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1021\/acs.jmedchem.5b01009","article-title":"Can invalid bioactives Undermine natural product-based drug discovery?","volume":"59","author":"Bisson","year":"2016","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100105_bib237","first-page":"655","article-title":"Why polyphenols have promiscuous actions? An investigation by chemical bioinformatics","volume":"11","author":"Tang","year":"2016","journal-title":"Nat Prod Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib238","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1038\/s41598-021-83032-3","article-title":"C-Glucosylation as a tool for the prevention of PAINS-induced membrane dipole potential alterations","volume":"11","author":"de Matos","year":"2021","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib239","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104321","article-title":"The flavones apigenin and luteolin induce FOXO1 translocation but inhibit gluconeogenic and lipogenic gene expression in human cells","volume":"9","author":"Bumke-Vogt","year":"2014","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib240","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.3892\/mmr.2015.3700","article-title":"Flavonoids from Triticum aestivum inhibit adipogenesis in 3T3-L1 cells by upregulating the insig pathway","volume":"12","author":"Poudel","year":"2015","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib241","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12967-017-1343-0","article-title":"Phenolic compounds apigenin, hesperidin and kaempferol reduce in vitro lipid accumulation in human adipocytes","volume":"15","author":"G\u00f3mez-Zorita","year":"2017","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100105_bib242","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1039\/C5FO00481K","article-title":"Kaempferol suppresses lipid accumulation by inhibiting early adipogenesis in 3T3-L1 cells and zebrafish","volume":"6","author":"Lee","year":"2015","journal-title":"Food Funct"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib243","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13105-018-0659-4","article-title":"Anti-obesity effects of kaempferol by inhibiting adipogenesis and increasing lipolysis in 3T3-L1 cells","volume":"75","author":"Torres-Villarreal","year":"2019","journal-title":"J Physiol Biochem"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100105_bib244","doi-asserted-by":"crossref","first-page":"12863","DOI":"10.1080\/07391102.2023.2273441","article-title":"Computational study on natural molecules targeting beta-ketoacyl reductase domain of fatty acid synthase for the identification of selective inhibitors","volume":"42","author":"Lakshmi Soukya","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.pharmr.2025.100105_bib245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fonc.2019.00487","article-title":"Reversal of multidrug resistance in cancer by multi-functional flavonoids","volume":"9","author":"Ye","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100105_bib246","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3390\/molecules23061246","article-title":"Special issue: Natural products: anticancer and beyond","volume":"23","author":"Cui","year":"2018","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100105_bib247","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib248","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13058-025-01991-1","article-title":"Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells","volume":"27","author":"Ward","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"7885","key":"10.1016\/j.pharmr.2025.100105_bib249","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-021-04075-0","article-title":"Dietary palmitic acid promotes a prometastatic memory via Schwann cells","volume":"599","author":"Pascual","year":"2021","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100105_bib250","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.19.00435","article-title":"Dietary modification and breast cancer mortality: long-term follow-up of the Women\u2019s Health Initiative randomized trial","volume":"38","author":"Chlebowski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.pharmr.2025.100105_bib251","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2016.72.0326","article-title":"Low-fat dietary pattern and breast cancer mortality in the Women\u2019s Health Initiative randomized controlled trial","volume":"35","author":"Chlebowski","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib252","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/13543784.2019.1657825","article-title":"Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1\/2 inhibitors","volume":"28","author":"Chen","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib253","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100105_bib254","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpdd.782","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a liver-targeting acetyl-CoA carboxylase inhibitor (PF-05221304): a three-part randomized Phase 1 study","volume":"9","author":"Bergman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100105_bib255","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100105_bib256","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1038\/s41598-024-58689-1","article-title":"SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia","volume":"14","author":"\u00c5backa","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100105_bib257","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115169","article-title":"A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters","volume":"404","author":"Wang","year":"2020","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:32:14Z","timestamp":1773966734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725075143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":257,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0031699725075143"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100105","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting fatty acid synthase for cancer drug discovery: Retrospective analyses and outlook","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100105"}}